Engflag

Solifenacin

Quick links to important sections

Solifenacin

Solifenacin_IT

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solifenacin

Quick Facts

Property Description
Active Ingredient Solifenacin succinate
Form Oral Tablet, Oral Suspension
Pharmacological Class Anticholinergic Agent (Muscarinic Receptor Antagonist)
Common Use Improving bladder control
Origin Synthetic (Quinuclidine derivative)

What Type of Medicine is Solifenacin?

Solifenacin is a synthetic, single-ingredient prescription medicine officially classified as an anticholinergic agent, specifically a muscarinic receptor antagonist. This classification is clinically recognized for its targeted effect on the involuntary nervous system. The compound is chemically a quinuclidine derivative. Solifenacin is recognized as a type of urinary antispasmodic because its action is focused on relaxing the smooth muscle of the bladder wall. It has a high affinity for specific muscarinic receptor subtypes, making it a targeted therapy.

Solifenacin Composition and Forms

The active ingredient is solifenacin succinate (INN), which is the compound responsible for producing the therapeutic effect. Solifenacin is manufactured for oral administration and is available as both an oral tablet and an oral suspension. This dual-form approach offers flexibility for different patient groups, including the availability of the suspension for those, such as children, who may have difficulty swallowing tablets. The succinate salt form is intentionally used to enhance the drug's stability and bioavailability when delivered using pharmaceutical excipients in these oral preparations, supporting its convenient once-daily approach.

General Purpose and High-Level Action

The general purpose of Solifenacin is to provide better bladder control by promoting the relaxation of the detrusor muscle, the muscle in the bladder wall. It works by acting as a blocker of chemical messengers that cause the bladder muscle to contract too frequently or involuntarily. By promoting the relaxation of the bladder wall muscle, the medication allows the bladder to hold a larger volume of urine. This essential action is intended to help reduce the sudden, intense urges to urinate (urinary urgency) and the resulting accidental leakage (urge urinary incontinence) that characterizes an overactive bladder.

What side effects are possible with Solifenacin?

Possible Side Effects and Safety Information

The safety profile of Solifenacin is primarily defined by effects related to its pharmacological classification as an anticholinergic agent. Adverse reactions are formally classified by frequency and System-Organ Class (SOC) in regulatory documents, with the most frequent effects being generally dose-dependent.

Frequency-Classified Adverse Reactions

The frequency of documented adverse reactions ranges from Very Common to Not Known, based on official regulatory data:

Frequency Classification Key Adverse Reactions
Very Common Dry mouth (Xerostomia)
Common Constipation, Blurred vision (Accommodation impairment), Nausea, Dyspepsia, Abdominal pain
Uncommon Urinary tract infection, Somnolence, Dry eye, Fatigue
Rare Urinary retention, Faecal impaction, Dizziness, Headache

Serious Adverse Reactions and Safety Constraints

Official labeling documents certain serious adverse reactions, which include anaphylactic reaction, Angioedema (potentially involving laryngeal swelling), and specific cardiac effects such as QT prolongation on ECG (frequency Not Known).

Regulatory documents outline population-specific safety limitations. Use is generally contraindicated in patients with severe hepatic impairment. A specific maximum dose restriction is defined for individuals with severe renal impairment, moderate hepatic impairment, and when the medicine is co-administered with potent CYP3A4 inhibitors. Caution is also specified for patients with bladder outflow obstruction or narrow-angle glaucoma.

Overdose and Emergency Response

Solifenacin Overdose and When to Seek Help

Overdose situations involving Solifenacin succinate are officially documented to present with exaggerated anticholinergic effects, reflecting an intensification of the drug's properties. Manifestations may include severe dry mouth, pronounced blurred vision, acute urinary retention, severe constipation, and central nervous system (CNS) symptoms such as confusion or somnolence.

Severe Manifestations and Required Actions

The regulatory profile identifies risks for life-threatening outcomes, particularly following massive overdose. These severe manifestations include tachycardia (rapid heart rate) and serious CNS effects such as hallucinations, delirium, and convulsions.

Immediate medical attention must be sought for any suspected overdose. For pronounced CNS effects or severe systemic symptoms, emergency services must be contacted immediately, as mandated by official guidance.

Official Management and Monitoring

Overdose management is symptomatic and supportive. The regulatory prescribing information notes that physostigmine may be administered for the reversal of severe central anticholinergic effects. Procedural steps described in regulatory sources include gastric lavage and the use of activated charcoal. Continuous monitoring is required due to the potential for systemic effects, with ECG monitoring recommended and hospitalization for observation for at least 24 hours sometimes required.

Therapeutic Uses of Solifenacin

What Solifenacin Treats: Main Uses and Benefits

Solifenacin is primarily indicated for the symptomatic management of overactive bladder (OAB). The medication is used for managing symptom clusters associated with OAB, including urge urinary incontinence, urinary urgency, and increased urinary frequency. It is applied across domains where additional symptomatic support is needed to help manage these disruptive manifestations.

Key Therapeutic Support

In clinical settings involving these acute or unstable symptom patterns, Solifenacin plays a role in managing symptoms that interfere with daily comfort. The medication may assist with symptomatic relief during phases of increased distress or discomfort.

“It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

This benefit assists with maintaining functional stability when symptoms become noticeable.

Quick Fact: Support for Overactive Bladder Symptoms A common clinical scenario is to help manage conditions characterized by periods of heightened symptoms, such as the sudden, intense need to urinate.

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population or Condition
Contraindicated Urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the active substance or excipients.
Contraindicated Patients with severe hepatic impairment (Child-Pugh C).
Contraindicated Patients with severe renal impairment or moderate hepatic impairment who are simultaneously taking a potent CYP3A4 inhibitor.
Use Allowed (Adults) Adults (18 years and older) are approved for overactive bladder symptoms.
Use Allowed (Pediatric) The oral suspension is approved for Neurogenic Detrusor Overactivity (NDO) in children aged 2 years and older. Safety and efficacy are not established in children younger than 2 years.

Condition-Based Restrictions

Use requires caution in patients with specific conditions, including clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, and controlled narrow-angle glaucoma. The use is not recommended in patients at high risk of QT prolongation.

For patients with severe renal impairment or moderate hepatic impairment (Child-Pugh B), the dose must be restricted to a 5 mg maximum daily limit. The maximum dose is similarly restricted to 5 mg when the medicine is used with a potent CYP3A4 inhibitor.

Reproductive Status

Clinical data for use during pregnancy is limited; it should be used only if the potential benefit justifies the potential risk. Use is generally advised to be avoided during lactation.

What should I know about interactions with other medicines?

Solifenacin Interactions with other medicines and products

Solifenacin is metabolized primarily by the liver enzyme Cytochrome P450 3A4 (CYP3A4). Interactions can occur based on how other medicines affect this enzyme and through additive pharmacodynamic effects.

Pharmacokinetic Interactions

Coadministration with potent CYP3A4 inhibitors, such as ketoconazole, significantly increases the blood concentration of solifenacin. This requires a dosage restriction: the daily dose of solifenacin should not exceed 5 mg when co-administered with a potent CYP3A4 inhibitor. This restriction is especially important for patients with severe renal impairment or moderate hepatic impairment. Solifenacin is not expected to cause clinically significant pharmacokinetic interactions with drugs that are substrates for many CYP enzymes, such as warfarin or digoxin.

Pharmacodynamic Interactions

Using solifenacin with other medicines that have anticholinergic properties can potentiate antimuscarinic effects, increasing the risk of adverse reactions like dry mouth, constipation, and urinary retention. Conversely, solifenacin can decrease the effectiveness of medicines that promote gastrointestinal motility (prokinetics). Due to the potential for QT interval prolongation, solifenacin is generally not recommended for individuals at high risk for this condition, including those taking other medications known to prolong the QT interval.

Mechanism of Action

Core Mechanism: Muscarinic Receptor Blockade

Solifenacin functions as a competitive antagonist primarily targeting the M3 receptor subtype located on the detrusor muscle cells of the urinary bladder wall. The molecule binds selectively to the receptor site, thereby preventing the endogenous neurotransmitter acetylcholine (ACh) from activating the receptor and initiating its signal.

Modulation of Cholinergic Signaling

The blockade of M3 receptors leads to the suppression of the cholinergic signal cascade mediating detrusor muscle contraction. This targeted pathway interference modulates heightened cholinergic signaling within the detrusor muscle, resulting in an alteration of muscle tone and involuntary contractility.

Physiological Consequence: Functional Volume Alteration

This reduction in detrusor muscle tone produces sustained smooth muscle relaxation during periods of volume change. This physiological adjustment is the basis for the resulting alteration of the bladder's functional volume capacity.

Dosage and Administration Information

How to Use Solifenacin

Solifenacin is administered via the oral route for both the tablet and oral suspension formulations. The medicine is taken once daily (q.d.), establishing a fixed 24-hour schedule for usage. Dosing is standardized to be taken with or without food.

Standard Labeled Dosing

The standard adult starting regimen is 5 mg taken once a day. If the initial dose is well tolerated, it may be increased to 10 mg once daily, which is the maximum recommended daily dose for this population.

Administration Requirements and Adjustments

Oral tablets must be swallowed whole with water and should not be chewed, crushed, or split to ensure proper drug delivery. If a patient misses a dose, the instruction is to take it as soon as it is remembered, unless it is already time for the next scheduled dose, in which case the missed dose should be skipped.

Population Group Maximum Daily Dose Restriction
Severe Renal Impairment (CLcr leq 30 mL/min) 5 mg once daily
Moderate Hepatic Impairment (Child-Pugh B) 5 mg once daily
Concomitant Potent CYP3A4 Inhibitors 5 mg once daily

For pediatric patients (2 years and older), the medication is used as an oral suspension with specific weight-based dosing. The dose is adjusted downwards to a maximum of 5 mg per day in adult patients who have moderate impairment of kidney or liver function or who are taking specific medications known as potent CYP3A4 inhibitors.

Recent Clinical Evidence

Research evidence / Overview of studies for Solifenacin

Evidence for Use in Overactive Bladder (OAB) Syndrome

The primary research for solifenacin in adults with Overactive Bladder (OAB) syndrome has utilized large, randomized controlled trials (RCTs). These are studies that compare the effects of the medicine against an inactive treatment, called a placebo, to observe and document variables over a defined time. These trials were designed to examine outcomes related to systemic or functional imbalance often associated with OAB, which is a condition characterized by fluctuating or episodic manifestations.

In these short-term trials, which typically lasted for 12 weeks, researchers used patient-kept urinary diaries to monitor several outcomes. These included monitoring variables such as the number of daily voiding events (urinary frequency) and the count of accidental urine leakage (urge urinary incontinence episodes). The evidence across the primary RCTs was reported to show agreement across key measured outcomes in these controlled settings. However, results apply only to the specific populations studied, and follow-up durations were limited in the primary efficacy studies.

Evidence for Use in Neurogenic Detrusor Overactivity (NDO)

Research for solifenacin's oral suspension formulation was conducted in patients with Neurogenic Detrusor Overactivity (NDO), a condition where research examined bladder muscle activity caused by a neurological condition. The studies explored this medicine in pediatric patients (children and adolescents).

These studies incorporated objective urodynamic parameters into their design. These measures assess objective bladder function, such as changes in Maximum Cystometric Capacity (MCC), which reflects the largest volume the bladder can hold during testing. Findings indicate that the research reported changes measured during the study period in the objective capacity of the bladder.

Long-Term Study and Follow-Up Data

While the main controlled trials lasted only a few months, open-label extension studies were applied in research contexts involving fluctuating or unstable symptoms. These extension studies monitored patients for longer observation periods, typically up to 40 to 52 weeks (approx. one year).

Research documented short-term changes and framed how patients reported their experience during the study period. However, long-term outcomes extending significantly beyond one year are not fully established in the primary research landscape. There is limited information for long-term outcomes, meaning data for maintaining measured change over many years are still emerging.

Key Studies & References

  1. Urinary incontinence and pelvic organ prolapse in women: management (NICE Guideline NG123)

Frequently Asked Questions (FAQ)

Common questions about Solifenacin (FAQ)

Q: What happens if I stop taking Solifenacin suddenly?

A: Official labeling does not provide descriptive information or instructions on the effects of suddenly stopping this medicine. Official information advises patients to consult a healthcare provider to discuss discontinuing the medicine.

Q: Can older adults take Solifenacin safely?

A: Studies have reported that the medicine is generally used at the lower strength, and studies have reported similar incidence and severity of common adverse events to those reported in younger patients. Official safety information notes that the medicine’s half-life (the time it takes for half the drug to be eliminated from the body) may be longer in this population.

Q: Is Solifenacin safe for people who have kidney problems?

A: Official prescribing information indicates that the use of Solifenacin is not recommended for patients with severe kidney disease. The medicine’s use is associated with a maximum dose restriction for individuals with severe renal impairment (a specific measure of reduced kidney function).

Q: Can people with liver issues use Solifenacin?

A: Official information states that the medicine is not recommended for patients with severe liver impairment (Child-Pugh C). For patients with moderate liver impairment (Child-Pugh B), the medicine’s use is associated with a maximum dose restriction.

Q: Can men with prostate issues still use Solifenacin?

A: Official safety information advises caution when using Solifenacin in patients with clinically important bladder outflow obstruction, which can be caused by prostate issues. This is due to the risk of urinary retention (the inability to fully empty the bladder). Official safety information indicates the medicine is generally not recommended for individuals with existing urinary retention.

Q: What does 'urinary retention' mean in the context of Solifenacin's safety information?

A: In the context of Solifenacin's safety information, urinary retention refers to the inability to partially or fully empty the bladder. Because Solifenacin affects bladder muscle control, it is listed as a serious potential risk or a condition for which the drug is generally not used.

Q: Does the efficacy of Solifenacin wear off over time?

A: Data from open-label extension studies, which have followed patients for up to one year, reported that the drug's effectiveness and tolerability generally did not diminish over the study period. Official regulatory information notes that long-term outcomes extending significantly beyond one year are still being evaluated.

Q: What is the main reason doctors prescribe Solifenacin?

A: Solifenacin is primarily prescribed for adults to manage the symptoms of Overactive Bladder (OAB) syndrome. It is also approved for use in pediatric patients (aged 2 years and older) for the treatment of Neurogenic Detrusor Overactivity (NDO).

Q: Is Solifenacin used to treat anything other than an overactive bladder?

A: Yes. Beyond Overactive Bladder (OAB) syndrome in adults, Solifenacin is also approved for use as an oral suspension in pediatric patients (aged 2 years and older) for the treatment of Neurogenic Detrusor Overactivity (NDO).

Q: Is Solifenacin the same type of drug as Oxybutynin?

A: Solifenacin is classified as an anticholinergic (or antimuscarinic) medicine. This classification describes a group of drugs that affect certain nerve signals in the body. Other medications used for overactive bladder, such as oxybutynin, also belong to this general class.

Q: Are there generic versions of Solifenacin available?

A: Yes, a generic version of Solifenacin succinate is generally available in the tablet formulation, providing a lower-cost alternative to the brand-name product.

Q: Can Solifenacin cause dry mouth, and if so, is it common?

A: Yes, dry mouth is a very common side effect reported in clinical trials for Solifenacin. It is the most frequently reported adverse event, with the incidence varying based on the prescribed strength.

Q: Is it normal to feel a bit dizzy when first starting Solifenacin?

A: Dizziness is a known side effect reported in clinical studies. Official safety information advises patients that Solifenacin may cause central nervous system (CNS) effects, and they should observe how the medicine affects them before engaging in activities like driving.

Q: Can Solifenacin affect sleep patterns?

A: Solifenacin has been associated with central nervous system effects such as somnolence (drowsiness) in some patients. Conversely, some research suggests that by reducing night-time urgency associated with OAB, the medicine may indirectly contribute to improved sleep quality for some individuals.

Q: Does Solifenacin affect blood pressure?

A: Clinical trials monitored changes in blood pressure. The average changes in systolic and diastolic blood pressure were reported to be small. However, official safety information lists hypertension (high blood pressure) as a less common adverse reaction reported during studies.

Q: Does Solifenacin affect driving ability or focus?

A: Yes. Solifenacin may cause anticholinergic central nervous system (CNS) effects, including somnolence (drowsiness), blurred vision, or confusion. Due to these risks, official information advises patients to observe how the medicine affects their alertness before driving or operating heavy machinery.

Q: Are there specific times of day that are better for taking Solifenacin?

A: The medicine is approved for once-daily use. Its long half-life allows it to be taken at any time of day, with or without food. Patients are generally advised to take it at a consistent time each day to help with adherence.

Q: Is Solifenacin considered a first-line treatment for overactive bladder?

A: Official drug documents confirm Solifenacin's established effectiveness in treating the symptoms of Overactive Bladder (OAB). The position of Solifenacin in a patient's overall treatment plan is determined by the prescribing healthcare provider based on established medical guidelines and individual circumstances.

Q: Can Solifenacin affect memory or thinking?

A: Solifenacin is associated with anticholinergic central nervous system (CNS) effects. Adverse reactions such as confusion and hallucinations have been reported. Official information describes these effects, and monitoring for them is common during treatment.

Q: Does Solifenacin cause constipation, and how can that be managed?

A: Constipation is a common side effect reported in clinical trials. As the medicine works by relaxing smooth muscle, it can affect the movement of the digestive tract. Product information describes the need for medical consultation if severe or prolonged constipation occurs.

Q: Can I use Solifenacin if I have a history of a certain type of heart issue?

A: Official safety information describes circumstances where caution is advised when using Solifenacin in patients with a known history of QT interval prolongation (a specific change in the heart's electrical rhythm). Caution is also advised for those taking other medicines that are known to affect the QT interval.

Q: Why do some people need a higher dose of Solifenacin than others?

A: Official information states the starting adult dose may be increased based on the patient's individual response to the initial dose and their tolerability of the medicine. The dose is also restricted for certain patient populations with existing conditions or those taking specific interacting medications.

Q: Is Solifenacin an antidepressant?

A: No. Solifenacin is classified as an anticholinergic (or antimuscarinic) medicine. It is a therapy used to modulate bladder muscle activity and is not approved for the treatment of depression or other mood disorders.

Q: Is there a link between Solifenacin and skin rash?

A: Yes. Rash and other skin reactions have been reported in safety information. Serious allergic reactions such as angioedema (swelling of the face, throat, tongue, or lips) have also been reported.

Q: Is Solifenacin safe to take during pregnancy (informationally descriptive)?

A: Official drug documents have classified Solifenacin for use during pregnancy. For instance, the U.S. FDA has assigned the medicine Pregnancy Category C, indicating that animal studies have shown potential adverse effects on the fetus.

Q: What are the official recommendations regarding alcohol consumption while on Solifenacin?

A: Official patient information describes limiting alcohol consumption while taking Solifenacin. Alcohol may increase the risk of certain central nervous system side effects associated with the medicine, such as dizziness or drowsiness.

Q: Are there known interactions between Solifenacin and herbal supplements?

A: Official information advises caution with substances that affect how the medicine is processed by the body. There is a potential for interactions with herbal supplements or dietary products that may influence this process.

Q: What is the difference between Solifenacin and other anticholinergic drugs?

A: Solifenacin is a selective antimuscarinic agent that primarily acts on the M3 receptor in the bladder wall. Studies comparing it to other anticholinergic drugs have reported differences mainly in the drug's selectivity and in the observed side effect profiles, such as the incidence of dry mouth and constipation.

Q: Is Solifenacin a controlled substance?

A: No. Solifenacin is classified as a prescription-only medicine but is not designated as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies.

How should Solifenacin be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Solifenacin

Scope Element Official Regulatory Requirement
Labeled storage temperature: Store at controlled room temperature (20 C to 25 C / 68 F to 77 F) with permitted excursions between 15 C and 30 C [FDA].
Protection requirements: Must be protected from light and excessive moisture [International Labeling]. Tablets should be kept in the original container.
Stability after opening: Solifenacin oral suspension must be discarded 28 days after the bottle is first opened.
Child-protection storage: The medicine must be stored out of the sight and reach of children. Tablet bottles typically include a child-resistant closure.
Disposal instructions: Unused or expired medication must be disposed of in accordance with local requirements [EMA/National Agencies].

These requirements define that Solifenacin must be stored within a specific controlled temperature range to protect the product's stability. Mandatory rules ensure child safety by requiring storage out of reach and through specialized packaging. Disposal must follow local regulatory procedures for unused medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Solifenacin found in:

A-Z Index: